KY 0201
Alternative Names: KY-0201Latest Information Update: 24 May 2024
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action CD47 antigen modulators; Programmed cell death-1 ligand-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral) (Novatim Immune Therapeutics pipeline, April 2024)